New Podcast: BTOG does … Tobacco Dependency in Lung Cancer. Dr Emma O’Dowd talks to Professor Sanjay Agrawal. Wherever you get your podcasts or listen online btog.org/btog-podcasts/ #LCSM #LungCancer
Jo Evans.
@oncolojo.bsky.social
Consultant medical oncologist @ Imperial College Healthcare NHS Trust (Thoracic Oncology, Acute Oncology), Honorary Senior Clinical Lecturer @ Imperial College. Mum to Mr11. Perpetually tired!
Delighted to share that Debra our Chair has been elected President of Lung Cancer Europe. She says, “As LuCE’s first patient President, I’m honoured to build on Anne-Marie’s leadership & continue strengthening the voice of people affected by #lungcancer across Europe.” #LCSM
Only 45% of eligible ALK+ #lungcancer patients in England got targeted treatment. People well enough to benefit didn’t get the drugs they needed. This isn’t good enough. #LCSM www.lungcanceraudit.org.uk/wp-content/u...
FLAURA2 regimen now reimbursed. I have some questions. Who needs chemo? Everyone? Selected pts? Access to other therapies - assume Impower150 not available to patient who have had Chemo-Osi? Is chemo-Osi likely better than sequencing Osi-IMPOWER 150? Lung cancer keeps getting more complex!
Read the April roundup of top stories from all 15 NIHR ARCs across the country 👇 mailchi.mp/nihr/april-2... Incuding the latest research, resources, blogs, awards, events, training & much more Join here to get this monthly roundup sent directly to your inbox: tinyurl.com/ARCsnewsletter
The NIHR Applied Research Collaborations (ARCs) April 2025 newsletter
The national newsletter from across all the NIHR ARCs. In this edition: Electric scooter schemes may reduce bicycle collisions by 20%, NIHR Impact Prize winners, a cost-effective anti-bullying program...
mailchi.mp
Mr11 has gone to #Nando’s to celebrate last day of term with his mates… means I get to eat stuff he won’t! Boom! Winner, winner salmon dinner!!
Pondering posting this since yesterday…. Yet another PIP report request asking when my patient with advanced lung cancer with brain mets might expect to be better from brain mets… is it appropriate to suggest they refer themself for brain imaging? 😡🤬😡🤬😡🤬🤬🤬
New review on ADCs in #lungcancer “These are now being explored in other oncogene-driven subsets, including ALK…” Still early days—but could help when TKIs stop working. Worth watching #LCSM www.cancertreatmentreviews.com/article/S030...
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target
With the increasing use of next-generation sequencing (NGS) for genomic profiling of lung cancer, it has been estimated that up to 50 % of non-squamous non-small cell lung cancer (NSCLC) may harbor an...
cancertreatmentreviews.com
Important & moving words from our amazing Fundraising Trustee Callum, who lost his mum to ALK+ #lungcancer last March. This September, he’s running 6 marathons in 6 days across 6 countries to raise global awareness for ALK+ lung cancer. #ALKpositive #LungCancerAwareness #LCSM
BTOG 2025 events for your diary ... BTOG/ @nlca-natcan.bsky.social State of the Nation Update Webinar – Thu 15 May ASCO Update Webinar June (date TBC) WCLC Update Webinar September (date TBC) continued...
It happens to be the 30 year anniversary of my Oxford Medical School graduation this year. This cartoon from the time of life predicted as a new NHS graduate hit the mark.
In 2021 I assumed my cough was from allergies & my chest pressure was work stress. It was stage 4 #lungcancer. An x-ray & biomarker testing saved my life. Had no idea that anyone can get lung cancer. 📺 interview from @younglungcancer.bsky.social 👉https://youtu.be/S50UEv81kS0?si=rixipm5FYbvOmpNx 🤍
@btog.bsky.social community, Assemble!
Roberto Borea MD@robertoboreamd.bsky.social · last yr.Now you can find the link to complete our @islb.info survey in the @oncoalert.bsky.social newsletter! 📨 It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide! bit.ly/43JzN03 @christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social
Now you can find the link to complete our @islb.info survey in the @oncoalert.bsky.social newsletter! 📨 It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide! bit.ly/43JzN03 @christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social
Unfortunately, my NIH grant (Columbia P50 center grant subcontract) was one of the awards terminated. A stop work order has been issued. We’re 8 months into the project— a community engaged study to ⬆️ 🫁 ca & CVD screening in nyc. I know many others affected as well. Hoping for reversal/resolution 😕
Jeremy Berg@jeremymberg.bsky.social · last yr.I have confirmation from several sources now that all T32s, many F30s and F31s, and most or all Center awards (P30, P50) have been terminated at Columbia. This is quite damaging to research and to individuals. This is pure terrorism and cannot be legal. But litigation will take time...
On the 5th Anniversary of Covid, I’m thinking of all those who lost their lives, including my cousin Julie Omar (Nee Harris), whose only error was going to work… www.bbc.co.uk/news/uk-engl...
Redditch nurse dies after developing Covid-19 symptoms
Julie Omar was a
bbc.co.uk
@annaminchom.bsky.social on newer small cell therapeutic strategies and management of CRS and ICANS as specific TRAEs With thought around timings of dose delivery and education of AOS teams and patients, safely deliverable within the NHS #BTOG25
With the successful role out of the TLHC programme, we now have a growing cohort of stage 1 SCLC patients. Hopefully this will become even more common, and work needed to understand optimal patient management @drjnaidoo.bsky.social #BTOG25
Graham Warren on smoking cessation in lung cancer pts. Extraordinary data: 🔺 $3.4bn cost of failed treatment if don’t quit 🔺 ⬇️ 45% mortality if quit 🔺Less frequent reminders more effective than more 🔺 Incredible ⬆️ survival if quit <6m after diagnosis: approx 4yr mOS benefit Sensational talk 🤯
Small cell in never smokers. On the rise for unknow reasons and a different biology. Having recently encountered my first patient who’s a never smoker(and no alcohol or recreational drugs), with extensive stage disease this insight is fascinating @stephenvliu.bsky.social #BTOG25
@drjnaidoo.bsky.social on the limited stage small cell space and the excitement around CCRT-Durvalumab. EAMS currently open in England… #BTOG25
@stephenvliu.bsky.social on excitement in the Small Cell arena. PDL1/PD1 inhibition a practice changer, but so many potential game changers on the horizon from BITES To ADC, it’s exciting to see new drugs for an area of unmet need #BTOG25
“We’re talking about people’s lives, not just pathways. If it was your life on the line you wouldn’t settle for 64 days of waiting.” Patient perspective on waits for genomic testing in #lungcancer at #BTOG25
Speed to diagnosis is key for ppl w #lungcancer- many of us are diagnosed at stage 4 when unwell. Great talk from Sandi Deans @nhsenglandldn.bsky.social Genomics at #BTOG25, illustrating the ideal pathway to reach the 14-day turnaround target in UK. Good to see ctDNA here #LCSM @btog.bsky.social
Magda Meissner on the Welsh ctDNA experience - an ‘in house’ solution assay wise and a huge amount of effort in validating and also learning to get more patients to test and more clinicians to genomic literacy #BTOG25
Debra Montague on ensuring the patient voice is not lost. The most important person in the room after all! We haven’t lost the patient voice but we all need to be better at listening! #BTOG25
Matthew Krebs on ctDNA and moving away from confirmatory tissue testing where an informative result is present. Key number 1% VAF for determining of non-actionable mutations are informative #BTOG25